Sublingual tryptase and ECP in children treated with grass pollen sublingual immunotherapy (SLIT): safety and immunologic implications.
BACKGROUND
The clinical safety of sublingual immunotherapy (SLIT) has been repeatedly confirmed; nevertheless, the possible onset of local oral symptoms is still a concern, and nothing is known about the pathogenesis of this effect. We aimed to determine whether the administration of SLIT in allergic children can evoke an IgE-mediated reaction, by measuring the levels of sublingual tryptase and ECP.


METHODS
Thirty children (7-12 years old) with allergic rhinitis/asthma due to grass pollen were prescribed SLIT. In these children, an allergen-specific nasal challenge was performed, and nasal tryptase and ECP were measured before and after. Sublingual ECP and tryptase were also assessed before the SLIT, after 1 month, and after 6 months of treatment. Ten matched allergic children and 10 healthy ones served as controls for the baseline levels of sublingual ECP and tryptase.


RESULTS
The levels of nasal tryptase and ECP significantly increased after nasal challenge (P<0.001), whereas no change during the SLIT course (at the beginning, after 1 month, and after 6 months) could be detected in sublingual tryptase either before or after SLIT administration. The sublingual ECP significantly decreased after 6 months of SLIT. The baseline levels of nasal tryptase and ECP were significantly higher in allergic subjects than in healthy controls, as was the level of sublingual ECP.


CONCLUSIONS
In the presence of an IgE-mediated reaction (ASNC), a significant increase of tryptase and ECP can be seen. When SLIT is administered, such a phenomenon does not occur; therefore, SLIT does not elicit any IgE reaction in the mouth. It is noteworthy that allergic subjects display higher levels of nasal ECP and tryptase than healthy subjects, even when symptom-free, and these observations may indicate the presence of subclinical inflammation.
Marcucci
F
F
Clinical Pediatrica, University of Perugia, Italy.
Sensi
L
L
Frati
F
F
Senna
G E
GE
Canonica
G W
GW
Parmiani
S
S
Passalacqua
G
G
D000286:Administration, Sublingual; D001249:Asthma / Q000188:drug therapy / Q000209:etiology; D001798:Blood Proteins / Q000008:administration & dosage*; D002648:Child; D002669:Child Welfare; D003888:Desensitization, Immunologic; D047091:Eosinophil Granule Proteins; D005260:Female; D006801:Humans; D008297:Male; D008517:Phytotherapy; D006109:Poaceae / Q000009:adverse effects; D011058:Pollen / Q000009:adverse effects; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy / Q000209:etiology; D012260:Ribonucleases; D012449:Safety; D012697:Serine Endopeptidases / Q000008:administration & dosage*; D013997:Time Factors; D053802:Tryptases
D001798:Blood Proteins; D047091:Eosinophil Granule Proteins; D012260:Ribonucleases; D012697:Serine Endopeptidases; D053802:Tryptases